Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

CCTC A Cambridge Cancer Trials Centre +44 (0)1223 348071
cuh.partner@nhs.net


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Back

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting

Open to: ALL

Age: 16.0 - 70.0

Dudley Bournemouth Southampton Worcester London Nottingham Ipswich Poole Colchester Peterborough London Huntingdon Cardiff Winchester Ayr Northwood Kidderminster Kilmarnock Cambridge Burton Upon Trent Manchester Wakefield Bedford Bristol Bury Saint Edmunds Redditch Romford Basingstoke Oxford Swansea

Medical Conditions

Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2016 Jun 2024

Publications

"Woitek R, McLean MA, Ursprung S, Rueda OM, Manzano Garcia R, Locke MJ, Beer L, Baxter G, Rundo L, Provenzano E, Kaggie J, Patterson A, Frary A, Field-Rayner J, Papalouka V, Kane J, Benjamin AJV, Gill AB, Priest AN, Lewis DY, Russell R, Grimmer A, White B, Latimer-Bowman B, Patterson I, Schiller A, Carmo B, Slough R, Lanz T, Wason J, Schulte RF, Chin SF, Graves MJ, Gilbert FJ, Abraham JE, Caldas C, Brindle KM, Sala E, Gallagher FA. Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. Cancer Res. 2021 Dec 1;81(23):6004-6017. doi: 10.1158/0008-5472.CAN-21-1499. Epub 2021 Oct 8."; "34625424"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.

Intervention Arm Group : Research 1;Research 2;

Intervention Type : DRUG
Intervention Description : Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.

Intervention Arm Group : Control;Research 1;Research 2;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Russells Hall Hospital
    Dudley
    DY1 2HQ
  • Royal Bournemouth Hospital
    Bournemouth
    BH7 7DW
  • Southampton General Hospital
    Southampton
    SO16 6YD
  • Worcestershire Royal Hospital
    Worcester
    WR5 1DD
  • Royal Free Hospital
    London
    NW3 2QG
  • Nottingham City Hospital
    Nottingham
    NG5 1PB
  • Ipswich Hospital
    Ipswich
    IP4 5PD
  • Poole Hospital
    Poole
    BH15 2JB
  • Colchester General Hospital
    Colchester
    CO4 5JL
  • Peterborough City Hospital
    Peterborough
    PE3 9GZ
  • University College London Hospital
    London
    NW1 2PG
  • Hinchingbrooke Hospital
    Huntingdon
    PE29 6NT
  • Velindre Cancer Centre
    Cardiff
    CF14 2TL
  • Royal Hampshire County Hospital
    Winchester
    SO22 5DG
  • University Hospital Ayr
    Ayr
    KA6 6DX
  • Mount Vernon Cancer Centre
    Northwood
    HA6 2RN
  • Kidderminster General Hospital
    Kidderminster
    DY11 6RJ
  • University Hospital Crosshouse
    Kilmarnock
    KA2 0BE
  • Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
    Cambridge
    Cambridgeshire
    CB2 0QQ
  • Queen's Hospital
    Burton Upon Trent
    Derby
    De13 ORB
  • The Christie
    Manchester
    Lancs
    M20 4GJ
  • Pinderfields General Hospital
    Wakefield
    Yorkshire
    WF1 4DG
  • Bedford General Hospital
    Bedford
  • Bristol Haematology & Cancer Centre
    Bristol
    BS2 8ED
  • West Suffolk Hospital
    Bury Saint Edmunds
    IP33 2QZ
  • The Alexandra Hopsital
    Redditch
    B98 7
  • Queen's Hospital
    Romford
    RM7 OAG
  • Basingstoke and North Hampshire Hospital
    Basingstoke
    RG24 9NA
  • Churchill Hospital
    Oxford
    OX3 7LE
  • Singleton Hospital
    Swansea
    SA2 8QA

CCTC A Cambridge Cancer Trials Centre +44 (0)1223 348071
cuh.partner@nhs.net



The study is sponsored by Cambridge University Hospitals NHS Foundation Trust and is in collaboration with AstraZeneca; Cancer Research UK.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03150576
Last updated 09 November 2022

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top